Denmark· DK-28106375119
Ultomiris
A ravulizumab product containing ravulizumab, registered in Denmark by Alexion Europe SAS. The same ATC class is registered in 12 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Ravulizumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L04AJ02 (ravulizumab), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 7 of them publish a price we can compare per daily dose
Ravulizumab · ATC L04AJ02
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Ravulizumab
- Manufacturer
- Alexion Europe SAS
- Country
- Denmark (DK)
- ATC code
- L04AJ02
- ATC class
- Ravulizumab
- Defined daily dose
- 70 mg, P
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28106375119
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
2 interactions on record for ravulizumab.
Graded by severity as the source publishes them — 2 minor. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ravulizumab · interactions on record
2 records
Same class
Other records under L04AJ02
Ravulizumab, as other registers publish it.
- United StatesUltomirisAlexion Pharmaceuticals Inc.
- NorwayUltomirisAlexion Europe SAS (2)
- FinlandUltomirisAlexion Europe SAS
- FinlandUltomirisAlexion Europe SAS
- FinlandUltomirisAlexion Europe SAS
- FinlandUltomirisAlexion Europe SAS
- NorwayUltomirisAlexion Europe SAS (2)
- United StatesUltomirisAlexion Pharmaceuticals Inc.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f07a1c79-66e9-4a06-b4ec-1d6fcade7a53 GET /v1/drugs/f07a1c79-66e9-4a06-b4ec-1d6fcade7a53?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "koncentrat til infusionsvæske, opløsning",
"source": "dkma",
"strength": "1100mg/11 ml",
"auth_role": "MOD",
"dk_drugid": "28106375119",
"substance": "Ravulizumab",
"auth_procedure": "Central",
"in_medicinpriser": true,
"registration_date_serial": "44153"
}See everything about ravulizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.